A major Cochrane review has found that drugs designed to target amyloid beta proteins in the brain are unlikely to provide meaningful benefits for patients. At the same time, these treatments appear to increase the risk of brain swelling and bleeding.
Amyloid beta is a protein that builds up in the brains of people with Alzheimer's disease, often years before symptoms appear. Scientists have long believed that removing these protein deposits could slow or prevent the disease. Based on this idea, several drugs have been developed to clear amyloid from the brain.
Large Review of Alzheimer's Drug Trials
The new analysis combined results from 17 clinical trials involving 20,342 participants. All of the studies focused on people with mild cognitive impairment or early-stage Alzheimer's dementia. Researchers have suggested that targeting amyloid early in the disease might offer the best chance of slowing progression.
Effects Fall Below Meaningful Clinical Thresholds
The findings showed that the impact of anti-amyloid drugs on memory decline and dementia severity was either nonexistent or extremely small. In fact, the measured effects were well below the level considered meaningful for patients in clinical practice.
"Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients," says lead author Francesco Nonino, neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy. "There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect. While early trials showed results that were statistically significant, it is important to distinguish between this and clinical relevance. It is common for trials to find statistically significant results that do not translate into a meaningful clinical difference for patients."
Increased Risk of Brain Swelling and Bleeding
Beyond the lack of benefit, the review also identified safety concerns. Anti-amyloid drugs were linked to a higher likelihood of swelling and bleeding in the brain. In many cases, these changes were only visible on brain scans and did not cause obvious symptoms. However, the long-term consequences remain uncertain because reporting of symptoms varied across studies.
Rethinking the Future of Alzheimer's Treatment
Based on these results, the researchers conclude that continuing to focus on removing amyloid beta is unlikely to lead to major improvements for patients. Although the drugs do reduce amyloid levels in the brain, this does not appear to translate into better outcomes.
The authors suggest that future research should shift toward other biological pathways involved in Alzheimer's disease. Many studies are already exploring alternative approaches.
"I see Alzheimer's patients in my clinic every week and I wish I had an effective treatment to offer them," says senior author Edo Richard, Professor of Neurology at Radboud University Medical Centre. "Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments. Sadly, anti-amyloid drugs do not offer this and bring additional risks. Given the absence of correlation between amyloid removal and clinical benefit, we need to explore other pathways to help address this devastating disease."
